ID   HeLa-mCAT#8 TAL-CERS2#18-CERT#10
AC   CVCL_B3T1
SY   TAL-CERS2#18-CERT#10
DR   Wikidata; Q110432878
RX   PubMed=27775668;
CC   Population: African American.
CC   Knockout cell: Method=TALEN; HGNC; 14076; CERS2 (Note=3 of 4 alleles).
CC   Knockout cell: Method=TALEN; HGNC; 2205; CERT1.
CC   Transfected with: MGI; MGI:88117; Slc7a1.
CC   Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) (HygR).
CC   Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
DI   NCIt; C27677; Human papillomavirus-related cervical adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_B3SX ! HeLa-mCAT#8 TAL-CERS2#18
SX   Female
AG   30Y6M
CA   Cancer cell line
DT   Created: 16-12-21; Last updated: 30-01-24; Version: 7
//
RX   PubMed=27775668; DOI=10.3390/ijms17101761;
RA   Yamaji T., Horie A., Tachida Y., Sakuma C., Suzuki Y., Kushi Y.,
RA   Hanada K.;
RT   "Role of intracellular lipid logistics in the preferential usage of
RT   very long chain-ceramides in glucosylceramide.";
RL   Int. J. Mol. Sci. 17:1761.1-1761.16(2016).
//